Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20543098
Lee SH, et al. (2010) Suppressor of cytokine signaling 2 regulates IL-15-primed human NK cell function via control of phosphorylated Pyk2. J Immunol 185, 917-28 20543098
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) no change compared to control

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) no change compared to control

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) increase shRNA decrease

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) increase shRNA decrease

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) no change compared to control

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) no change compared to control

Y402-p - Pyk2 (human)
Modsite: CsIEsDIyAEIPDEt SwissProt Entrez-Gene
Orthologous residues
Pyk2 (human): Y402‑p, Pyk2 iso2 (human): Y402‑p, Pyk2 (mouse): Y402‑p, Pyk2 (rat): Y402‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-15 decrease
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
SOCS2 (human) Induces co-immunoprecipitation
Comments:  NK cell effector functions

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) increase shRNA decrease

Y525-p - Syk (human)
Modsite: ALRADENyykAQtHG SwissProt Entrez-Gene
Orthologous residues
Syk (human): Y525‑p, Syk iso2 (human): Y502‑p, Syk (mouse): Y519‑p, Syk (rat): Y519‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) increase shRNA decrease

Y526-p - Syk (human)
Modsite: LRADENyykAQtHGK SwissProt Entrez-Gene
Orthologous residues
Syk (human): Y526‑p, Syk iso2 (human): Y503‑p, Syk (mouse): Y520‑p, Syk (rat): Y520‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic myelogenous leukemia
Relevant cell lines - cell types - tissues:  K562 (erythroid), NK92 (natural killer cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
SOCS2 (human) increase shRNA decrease